Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US6448077B1 · kind B1 · utility
17Cited by
5References
38Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 10, 1997 |
| Grant date | Sep 10, 2002 |
| Priority date | — |
| Expiry date | Nov 10, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Chimeric and humanized monoclonal antibodies that specifically bind to an extracellular domain of a VEGF receptor and neutralize activation of the receptor are provided. In vitro and in vivo methods of using these antibodies are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.